Odefsey
NDC Package 50090-2340-0
Package Information
Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years of age and older as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY [see Microbiology (12.4) and Clinical Studies (14)]. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-2340 and is authorized under FDA application NDA208351.
Identification & Billing
- RxCUI: 1741733 - emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet
- RxCUI: 1741733 - emtricitabine 200 MG / rilpivirine 25 MG (as rilpivirine HCl 27.5 MG) / tenofovir alafenamide 25 MG (as tenofovir alafenamide fumarate 28 MG) Oral Tablet
- RxCUI: 1741739 - ODEFSEY 200 MG / 25 MG/ 25 MG Oral Tablet
- RxCUI: 1741739 - emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet [Odefsey]
- RxCUI: 1741739 - Odefsey (emtricitabine 200 MG / rilpivirine 25 MG (as rilpivirine HCl 27.5 MG) / tenofovir alafenamide 25 MG (as tenofovir alafenamide fumarate 28 MG)) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-2340 - Odefsey
- 50090-2340-0 - 30 TABLET in 1 BOTTLE, PLASTIC
- 50090-2340 - Odefsey
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-2340-0 identifies a specific commercial package of 30 tablet in 1 bottle, plastic of Odefsey, labeled by A-s Medication Solutions. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by A-s Medication Solutions on March 01, 2016. The current certification is valid through December 31, 2019.
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090234000. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.